Mission Statement

Share article


OncoLink is the first multimedia oncology information resource placed on the Internet. OncoLink's mission is consistent with that of the University of Pennsylvania Medical Center, and the Abramson Cancer Center of the University of Pennsylvania which has sanctioned its use and development. OncoLink is accessible worldwide to anyone with Internet access, and there is no charge for its use. OncoLink has been established with the following objectives:

  1. Dissemination of information relevant to the field of oncology,
  2. Education of health care personnel,
  3. Education of patients, families, and other interested parties, and
  4. Rapid collection of information pertinent to the specialty.


News
Inform Dual ISH test determines if breast cancer patients are candidates for trastuzumab

Jun 16, 2011 - The U.S. Food and Drug Administration has approved the Inform Dual ISH test, a genetic test to determine whether women with breast cancer are human epidermal growth factor receptor 2-positive and therefore candidates for trastuzumab (Herceptin).



I Wish You Knew

How cancer patients have changed my life

View More



Blogs and Web Chats

OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.




OncoLink OncoPilot

Facing a new cancer diagnosis or changing the course of your current treatment? Let our cancer nurses help you through!

Learn More